Loading clinical trials...
Loading clinical trials...
A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS)
Conditions
Interventions
ASTX727 Dose Escalation
ASTX727 Dose Confirmation
+1 more
Locations
17
United States
Mayo Clinic
Phoenix, Arizona, United States
University of Southern California
Los Angeles, California, United States
University of Chicago
Chicago, Illinois, United States
Horizon Oncology
Lafayette, Indiana, United States
Johns Hopkins
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Start Date
October 28, 2014
Primary Completion Date
June 5, 2018
Completion Date
December 4, 2019
Last Updated
August 27, 2024
NCT06303193
NCT05564390
NCT03050268
NCT06847867
NCT05969860
NCT06439199
Lead Sponsor
Astex Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions